Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Breast 2

Conditions

Melanoma 3Neoplasm Metastasis 2Skin Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 36Cyclophosphamide 24Nivolumab 23Ipilimumab 22aldesleukin 19Interleukin-2 15fludarabine 14Specimen Handling 12Dacarbazine 11fludarabine phosphate 10Magnetic Resonance Spectroscopy 10Temozolomide 9Radiosurgery 9Biopsy 9cemiplimab 8Paclitaxel 8dabrafenib 5binimetinib 5Vemurafenib 5Radiotherapy 5Carboplatin 5trametinib 4sargramostim 4encorafenib 4avelumab 4Pemetrexed 4Leucovorin 4Fluorouracil 4Cisplatin 4Bevacizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Antibodies, Monoclonal × Dermatologic × Clear all
NCT01335009 2021-09-01

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Eisai Inc.

Phase 2 Completed
76 enrolled 13 charts
Dermatologic

Melanoma, Neoplasm Metastasis

NCT00094653 2011-07-11

MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma

Bristol-Myers Squibb

Phase 3 Completed
1,783 enrolled 29 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡